These days, one can almost be convinced of the reality of a truly efficient market, one that brings together buyers and sellers, matching excess capacity with need. The Internet promises to make this possible, by acting as the ultimate go-between. It is not only the purveyors of products that have realized the potential of the Internet's connectivity. Recently, several sites have gone up to facilitate the buying and selling of certain fungible but less tangible assets of R&D based companies. Yet2.com, Pharmalicensing.com,and PL-X.com all have web sites that seek to match buyers and sellers in technology transfer. PharmaUniverse.com hopes to create an efficient market for other pharmaceuticals assets like short-dated inventory or manufacturing capacity.
The Web, as E-Bay has definitively shown, can create relatively
efficient markets, bringing together diverse buyers and sellers.
Health care has seen a number of marketing and distribution plays,
like Ventro Corp. , Neoforma.com
Inc. , and MedAssets.com Inc.
Now companies are starting up to broker the often less obvious assets of the industry. The founders of drug delivery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.
The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
